Steve Brozak specializes in health research and banking across many segments. Right now Mr. Brozak is seeing one of the most significant demands for innovation. He says there is a limited availability of money to fund research and pay for drugs, and he is seeing more financial calculations based on revenue that shouldn’t be rewarded, as well as companies making incremental improvements of older drugs being rewarded. He says resources are being wasted to support these types of activities. Mr. Brozak is looking forward to seeing some pushback, and he’s starting to see some around the periphery. He discusses five companies with novel drugs that investors should be noting.
Full interview available here.
Crohn's Disease Cure Results from this Biotech Top Pick from Dr. Steve Brozak
March 27, 2019
Steve Brozak Wants MASP-2 Targeting for COVID 19 Treatment
October 04, 2021
Interview Highlights: Joseph Walewicz of Laurentian Bank Securities on Biotechnology and Pharmaceuticals
August 22, 2016
Interview Highlights: Gbolahan Amusa of Chardan Capital Markets on Biotechnology and Pharmaceuticals
August 22, 2016
Interview Highlights: Ryan Hutchinson of Guggenheim Securities on Data Hosting Centers and Data Storage
September 20, 2016
